CSPC says FDA clears CRB-701 pivotal trial in second-line oropharyngeal cancerPUBT·1 day ago, 07:34 AMCRBP+1.46%01093-2.40%
CSPC PHARMA Marketing Application for Sirolimus for Injection AcceptedAASTOCKS News·2 days ago, 09:07 PM01093-2.40%
CSPC PHARMA HA1406 Enteric-coated Tablets for Depression Treatment Meet Primary Endpoint in Phase III Clinical TrialAASTOCKS News·2 days ago, 09:07 PM01093-2.40%
Morgan Stanley Remains a Buy on CSPC Pharmaceutical Group (CHJTF)Tip Ranks·1 day ago, 07:36 PM01093-2.40%
CSPC says China NMPA accepts sirolimus albumin-bound injection filing, grants priority reviewPUBT·Jul 27 at 07:58 AM01093-2.40%300765-5.26%
CSPC PHARMA Expects Interim Consolidated Profit of Approximately RMB5.9B-6.2BAASTOCKS News·Jul 27 at 04:44 AM01093-2.40%300765-5.26%
CSPC Innovation Pharma, CSPC Pharmaceutical Group unit, forecasts H1 net profit at 1.18 billion-1.36 billion yuanPUBT·Jul 27 at 04:34 AM01093-2.40%300765-5.26%
CSPC Pharma expects H1 profit attributable to owners at RMB 5.9 billion-RMB 6.2 billionPUBT·Jul 27 at 04:32 AM01093-2.40%AZN-1.13%
CSPC Sees Profit Surge on AstraZeneca Deal and Solid Drug SalesTip Ranks·Jul 27 at 04:37 AM01093-2.40%AZN-1.13%
Nomura Cuts CSPC PHARMA TP to HKD10.31, Expects Mild Growth in 2Q Drug SalesAASTOCKS News·Jul 26 at 10:47 PM01093-2.40%
Nomura Expects AKESO to Swing to Interim Profit of RMB46M, Maintains Buy RatingAASTOCKS News·Jul 26 at 11:59 PM09926-2.56%
Nomura Raises WUXI BIO TP to HKD51.38, Estimates 1H Profit to Drop 15%AASTOCKS News·Jul 27 at 02:22 AMWXXWY-3.96%02269-4.01%
WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMOPR Newswire·1 day ago, 09:27 PMWXXWY-3.96%02269-4.01%
WuXi Biologics added to FTSE4Good Index Series for sixth straight yearPUBT·1 day ago, 09:28 PMWXXWY-3.96%02269-4.01%
